Health Canada has approved INVOKANA®* (canagliflozin) for reduction of major adverse cardiovascular events (MACE), the first SGLT2 inhibitor in Canada to receive this indication(1)

Wednesday, October 17, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

1

INVOKANA® Product Monograph, October 15, 2018.

2

INVOKANA® Product Monograph, October 15, 2018.

3

INVOKANA® Product Monograph, October 15, 2018.

4

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017.

5

INVOKANA® Product Monograph, October 15, 2018.

6

INVOKANA® Product Monograph, October 15, 2018.

7

INVOKANA® Product Monograph, October 15, 2018.

8

Diabetes Canada. 2018 National Backgrounder. Available at: http://www.diabetes.ca/getmedia/6960f8d5-0869-4233-8ac2-6c669dae7c59/2018-Backgrounder-Canada_KH_AB_KB-edited-13-March-2018_2.pdf.aspx. Accessed August 29, 2018.     

9

Diabetes Canada. 2018 National Backgrounder. Available at: http://www.diabetes.ca/getmedia/6960f8d5-0869-4233-8ac2-6c669dae7c59/2018-Backgrounder-Canada_KH_AB_KB-edited-13-March-2018_2.pdf.aspx. Accessed August 29, 2018.

10

Diabetes Canada. Heart Disease and Stroke. Available at: https://www.diabetes.ca/diabetes-and-you/complications/heart-disease-stroke. Accessed August 26,2018.

11

Public Health Agency of Canada. (2011). Diabetes in Canada: Facts and figures from a public health perspective. Ottawa, Ont.: Public Health Agency of Canada. Retrieved from https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/cdmc/publications/diabetes-diabete/facts-figures-faits-chiffres-2011/pdf/facts-figures-faits-chiffres-eng.pdf. Accessed August 29, 2018. 

12

Institute for Clinical Evaluative Sciences. (2003). Diabetes in Ontario: An ICES Practice Atlas. Retrieved from http://www.ices.on.ca/Publications/Atlases-and-Reports/2003/Diabetes-in-Ontario.aspx. Accessed August 29, 2018.

13

Asif M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. J  Educ Health Promot. 2014;3:1.

14

INVOKANA® Product Monograph, October 15, 2018.

15

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017.

16

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017.

17

INVOKANA® Product Monograph, October 15, 2018.

18

INVOKANA® Product Monograph, October 15, 2018.

19

INVOKANA® Product Monograph, October 15, 2018.

20

INVOKANA® Product Monograph, October 15, 2018.

21

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017.

22

INVOKANA® Product Monograph, October 15, 2018.

23

INVOKANA® Product Monograph, October 15, 2018.

24

INVOKANA® Product Monograph, October 15, 2018.

25

INVOKANA® Product Monograph, October 15, 2018.

26

INVOKANA® Product Monograph. October 15, 2018.

27

Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store